This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: Halozyme, Hewlett-Packard, Immunogen, Sprouts


Halozyme Therapeutics (HALO) was upgraded at UBS to buy from neutral, UBS said. Driven on pipeline potential and undervalued valuation, UBS said. Twelve-month price target is $16.

Hewlett-Packard (HPQ - Get Report) was upgraded at Goldman Sachs to neutral from sell. Management has executed far more effectively than anticipated, Goldman Sachs said. Twelve-month price target is $32.

Immunogen (IMGN - Get Report) was upgraded at UBS to neutral from sell. Bullish outlook on Kadcyla and royalty revenue providing lower-risk valuation support, UBS said. Twelve-month price target is $13.

Points International (PCOM) was downgraded to hold at TheStreet Ratings.

Phoenix Companies (PNX) was upgraded to hold at TheStreet Ratings.

Springleaf (LEAF) was downgraded at Sterne Agee to neutral. Twelve-month price target is $28. Estimates were also cut, because of weakness in two units, Sterne Agee said.

Sprouts (SFM) was upgraded at Credit Suisse to outperform from neutral. Twelve-month price target is $34. Pullback provides an opportunity, Credit Suisse said. Twelve-month price target is $34.

Triumph (TGI) was upgraded at Credit Suisse to outperform from neutral. Company offers growth at a reasonable price, Credit Suisse said. Twelve-month price target is $88.

Theravance (THRX) was downgraded at Robert Baird to hold from buy. Valuation call, following the recent split, Robert Baird said.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.

Kass: Turn, Turn, Turn
Why Amazon Loves Local, and Why It Absolutely Shouldn't

This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HPQ $11.59 0.00%
IMGN $6.17 0.00%
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs